Last reviewed · How we verify
Ramipril Oral Product
Ramipril Oral Product, marketed by Vastra Gotaland Region, holds a position in the cardiovascular market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Ramipril Oral Product |
|---|---|
| Also known as | ACE inhibitor |
| Sponsor | Vastra Gotaland Region |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- STunning in Acute Myocardial Infarction - BAS (PHASE4)
- Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. (PHASE4)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PHASE3)
- A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril Oral Product CI brief — competitive landscape report
- Ramipril Oral Product updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI